1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Patterson Veterinary

Sort By:
Title
Replies Views
Last Message ↓
  1. anonymous
    Replies:
    31
    Views:
    11,732
  2. anonymous
    Replies:
    0
    Views:
    1,609
  3. anonymous
    Replies:
    3
    Views:
    3,600
  4. Anonymous
    Replies:
    9
    Views:
    8,695
  5. Anonymous
    Replies:
    8
    Views:
    5,392
  6. anonymous
    Replies:
    1
    Views:
    2,642
  7. Fur baby warrior
    Replies:
    3
    Views:
    1,899
  8. Anonymous
    Replies:
    23
    Views:
    12,988
  9. anonymous
    Replies:
    1
    Views:
    2,256
  10. Anonymous
    Replies:
    7
    Views:
    8,380
  11. Anonymous
    Replies:
    1
    Views:
    1,886
  12. Anonymous
    Replies:
    2
    Views:
    4,761
  13. Anonymous
    Replies:
    0
    Views:
    1,988
  14. Anonymous
    Replies:
    3
    Views:
    4,291
  15. Anonymous
    Replies:
    0
    Views:
    3,717
  16. Anonymous
    Replies:
    1
    Views:
    2,677
  17. Anonymous
    Replies:
    1
    Views:
    3,686
  18. Anonymous
    Replies:
    3
    Views:
    3,695
  19. Anonymous
    Replies:
    7
    Views:
    5,797
  20. Anonymous
    Replies:
    4
    Views:
    4,219

Thread Display Options

Loading...